Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety

Therapeutic Advances in Endocrinology and Metabolism

Volumn 9, Issue 1, 2018, Pages 15-28

  Mills, Elizabeth P ^a   Brown, K Paige D ^a   Smith, Jennifer D ^b   Vang, Phillip W ^a   Trotta, Katie ^a  

^a CAMPBELL UNIVERSITY   (United States)

^b WJB Dorn VA Medical Center   (United States)

Author keywords

diabetes; glucagon like peptide 1 receptor agonists; nonalcoholic fatty liver disease; statin; steatohepatitis; thiazolidinediones; treatment; type 2

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOTRANSFERASE; ANTILIPEMIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

BODY WEIGHT LOSS; DRUG EFFICACY; DRUG SAFETY; FIBROSIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 85044296048     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018817741852     Document Type: Review

References (35)

1. Angulo P., Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–1231.
2. Farrell GC, Larter CZ., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl. 1): S99–S112.
3. Buzzetti E, Pinzani M, Tsochatzis EA., The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038–1048.
4. Li Y, Liu L, Wang B. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep 2013; 1: 57–64.
5. Loomba R, Lutchman G, Kleiner DE. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172–182.
6. Bellentani S, Scaglioni F, Marino M. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155–161.
7. Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811–826.
8. Nair S, Diehl AM, Wiseman M. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23–28.
9. Mazza A, Fruci B, Garinis GA. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012; 2012: 716404.
10. Haukeland JW, Konopski Z, Eggesbo HB. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853–860.
11. Nar A, Gedik O., The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009; 46: 113–118.
12. Yki-Jarvinen H., Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.
13. Shulman GI., Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171–176.
14. Riera-Guardia N, Rothenbacher D., The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 2008; 10: 367–375.
15. Cunard R, Ricote M, DiCampli D. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002; 168: 2795–2802.
16. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008–1017.
17. Ratziu V, Giral P, Jacqueminet S. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008; 135: 100–110.
18. Torres DM, Jones FJ, Shaw JC. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011; 54: 1631–1639.
19. Omer Z, Cetinkalp S, Akyildiz M. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 18–23.
20. Gastaldelli A, Harrison SA, Belfort-Aguilar R. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50: 1087–1093.
21. Belfort R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297–2307.
22. Cusi K, Orsak B, Bril F. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016; 165: 305–315.
23. Uccellatore A, Genovese S, Dicembrini I. Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists. Diabetes Ther 2015; 6: 239–256.
24. Pyke C, Heller RS, Kirk RK. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280–1290.
25. Armstrong MJ, Houlihan DD, Rowe IA. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013; 37: 234–242.
26. Armstrong MJ, Gaunt P, Aithal GP. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679–690.
27. Fan H, Pan Q, Xu Y. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol 2013; 57: 702–708.
28. Shao N, Kuang HY, Hao M. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 2014; 30: 521–529.
29. Kimura Y, Hyogo H, Yamagishi S. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750–757.
30. Kiyici M, Gulten M, Gurel S. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713–718.
31. Han KH, Rha SW, Kang HJ. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol 2012; 6: 340–351.
32. Hyogo H, Tazuma S, Arihiro K. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711–1718.
33. Abel T, Feher J, Dinya E. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009; 15: MS6–MS11.
34. Nelson A, Torres DM, Morgan AE. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990–994.
35. Baffy G., Hepatocellular carcinoma in non-alcoholic fatty liver disease: epidemiology, pathogenesis, and prevention. Journal of Clinical and Translational Hepatology 2013; 1: 131–137.